Copper Histidine

Small molecule

CCyprium Therapeutics, Inc.

Copper Histidine is one of 8 small molecule programs targeting Menkes disease. It is currently in development.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Menkes DiseaseActive, not recruiting

Menkes DiseasePhase 1/Phase 2

Active, not recruiting

Competition

Competitive Landscape

9 competitors in Menkes Disease

#DrugCompanyPhaseTrials

Fludara

Jakafi

Vidaza

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Busulfex

Dacogen

Alkeran

Northera

2 8

Copper Histidine

CCyprium Therapeutics, Inc.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Menkes disease2 trials

Molecular Bases of Response to Copper Treatment in Menkes Disease, Related Phenotypes, and Unexplained Copper Deficiency

Completed·CCyprium Therapeutics, Inc.·Phase 3·NCT00811785·93 enrolled

Copper Histidine Therapy for Menkes Diseases

Completed·EEunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)·Phase 1/2·NCT00001262·60 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Copper Histidine. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Copper Histidine compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Copper Histidine. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Cyprium Therapeutics, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Company: CCyprium Therapeutics, Inc.

Copper Histidine

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Menkes disease2 trials

References

Drug Info

Quick Facts

Related News